2 Cancer Stocks That Could Make You Filthy Rich [The Motley Fool]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: The Motley Fool
The COVID-9 pandemic has done a number on global stock markets this year. Several multibillion-dollar industries, such as airlines, cruise ships, and upscale sit-in restaurants, among many others, are fighting for their very survival right now.Pharmaceutical companies, especially those specializing in cancer treatments, are a different story altogether, though. While airlines and cruise ships may struggle to regain their footing in the months ahead, cancer companies should quickly get back to business as usual post-pandemic. Most cancer patients, after all, aren't likely to skip out on life-saving treatments unless they absolutely have to. So, once the COVID-9 threat fades, cancer stocks should be among the first to truly rebound.Which cancer stocks are poised for the biggest gains at the end of this global pandemic?Exelixis(NASDAQ:EXELImmunomedics, Inc.NASDAQ:IMMUImage source: Getty Images.Exelixis: a proven cash cow with several catalysts on the wayExelixis is a mid-cap cancer compa
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025Business Wire
- Exelixis (NASDAQ:EXEL) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]Seeking Alpha
- Company News for Nov 6, 2025 [Yahoo! Finance]Yahoo! Finance
- Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still [Seeking Alpha]Seeking Alpha
EXEL
Earnings
- 11/4/25 - Beat
EXEL
Sec Filings
- 12/5/25 - Form 4
- 11/26/25 - Form 4
- 11/24/25 - Form 4
- EXEL's page on the SEC website